Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Prof. Biree Andemariam
University of Connecticut Health, Farmington, CT, USA
Prof. Andemariam is professor of medicine and the American Red Cross Endowed Chair at the University of Connecticut School of Medicine, CT, USA. She is a physician scientist in the Division of Hematology/Oncology, founding director of the New England Sickle Cell Institute and director of the Connecticut Bleeding Disorders Center. read more
Prof. Andemariam has been lead principal investigator of several global sickle cell disease clinical trials and registry studies. Her research interests include defining the intracellular signalling pathways involved in sickle vaso-occlusion and developing/implementing care pathways that lead to improved patient outcomes and health resource utilization.
Disclosures
Prof. Biree Andemariam discloses: Grants/research support from Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk and Pfizer. Consulting fees from Accordant, Emmaus (Relationship Terminated) and GlaxoSmithKline. Advisory board or panel fees from Afimmune, Agios Pharmaceuticals, Bluebird Bio, Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk, Pfizer, Sanofi Genzyme and Vertex Pharmaceuticals.
Prof. Modupe Idowu
University of Texas Health Science Center, McGovern Medical School, Houston, TX, USA
Prof. Idowu is professor of medicine in the Division of Hematology at the University of Texas (UT) Health Science Center, McGovern Medical School in Houston, TX, USA. She is the director of the Division of Hematology, associate programme director of the Hematology/Oncology Fellowship and medical director of UT Physicians Comprehensive Sickle Cell Center. read more
Prof. Idowu is an active member of the American Society of Hematology, American Federation for Medical Research and the National Medical Association. Her clinical interests include sickle cell anaemia, other anaemias, thrombocytopenia, leukopenia and bone marrow disorders. In addition to serving as principal investigator for more than 12 clinical trials, Prof. Idowu is also a reviewer for numerous scientific journals.
Disclosures
Prof. Modupe Idowu discloses: Grants/research support from Agios Pharmaceuticals, Alexion, Forma, Global Blood Therapeutics, Novartis, Novo Nordisk and Pfizer. Consulting fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Advisory board or panel fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Speaker’s bureau fees from Global Blood Therapeutics.
Prof. Mark C Walters
University of California, San Francisco, Oakland, CA, USA
Prof. Walters is the Jordan Family Director of the Blood and Marrow Transplantation Program at University of California San Francisco (UCSF) Benioff Children’s Hospital, Oakland, CA, USA. He is professor and chief of the Hematology Division in the Department of Pediatrics at UCSF School of Medicine, and is programme director of the California Institute of Regenerative Medicine Alpha Stem Cell Clinic at UCSF. read more
Prof. Walters is active in cooperative clinical transplantation trials and has led several National Institutes of Health-supported investigations of haematopoietic cell transplantation for sickle cell anaemia and thalassaemia. His research interests include haematopoietic cell transplantation for haemoglobin disorders, novel cellular therapies for non-malignant haematological disorders, and the use of genomic editing and gene addition therapies as a strategy to extend curative therapy in patients with a clinically significant haemoglobinopathy.
Disclosures
Prof. Mark C Walters discloses: Consulting fees from AllCells and BioChip Labs. Advisory board or panel fees from Ensoma and Vertex Pharmaceuticals.
